FiercePharma16h
Regulatory tracker: Europe approves CSL's HAE drug, Arcturus-partnered COVID vaccine
Galderma's efforts to expand the market for Nemluvio are bearing more fruit ... During the open-label extension phase of the study, Beyonttra demonstrated a relative risk reduction in deaths ...
dermatologyadvisor6d
The Role of IL-31 in Itch, Inflammation, and Skin Barrier Dysfunction in Prurigo Nodularis - Dermatology Advisor
2,3 Historically, PN treatment has relied on off-label therapies, such as corticosteroids ... Galderma receives U.S. FDA approval for Nemluvio ® (nemolizumab) for patients with moderate-to-severe ...
Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization In The United Kingdom And Switzerland For Moderate-To...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
Yahoo Finance4d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the ...
Morningstar4d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...
Yahoo Finance4d
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis (AD), becoming the latest pharmaceutical ...
Yahoo Finance5d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
This approval from the European Commission is based on robust results from the phase III OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the significant ...